A question has puzzled researchers and clinicians as worldwide cannabis use has risen: Why do certain people who try cannabis never develop a problem with addiction, while roughly one in 10 progresses to cannabis use disorder?
A new study supported by the Yale Center for the Science of Cannabis and Cannabinoids (YC-SCAN2 ) provides a comprehensive genetic answer. By analyzing data from the entire genome and multiple types of brain imaging, the research team discovered that cannabis use and cannabis use disorder are linked to different patterns of brain structure and function, driven by different genes and biological processes.
The findings, published in Neuropsychopharmacology, suggest that the leap from recreational use to addiction is not simply a matter of "more of the same," but instead reflects a fundamentally different neurobiological trajectory.
The researchers examined thousands of brain imaging-derived phenotypes—measurable features of brain structure and function captured by magnetic resonance imaging (MRI)—and tested which ones shared genetic architecture with cannabis use versus cannabis use disorder. The results were striking in their specificity.
Cannabis use was genetically linked to the default mode network—a brain system active during daydreaming, self-referential thought, and mind-wandering—as well as to the functional connection between the default mode network and the central executive network, which governs planning and decision making.
Cannabis use disorder, by contrast, was linked to the connection between the default mode network and the salience network—a system that detects important stimuli and toggles between internal reflection and external attention—and to the microstructure of white matter tracts, the brain's long-range communication cables.
"We've long known that cannabis use and cannabis use disorder are not the same thing, but our study highlights that their genetic predisposition is at least partially linked to distinct parts of the brain," says Renato Polimanti, PhD, associate professor of psychiatry and senior author of the study. "It tells us that the transition from use to disorder is not just a quantitative escalation, but a qualitative shift in the neurobiology involved."
These findings arrive at a time of shifting cannabis policy and rising use rates globally. By demonstrating that use and disorder are neurobiologically distinct, the study has implications for how clinicians screen for risk, how researchers design prevention and treatment studies, and how the public understands cannabis-related harm.
"As cannabis becomes more accessible, it's critical that we distinguish between the biology of use and the biology of addiction," Polimanti says. "Treating them as the same phenomenon would miss the very mechanisms we most need to understand and intervene on."
“Differentiating the neurobiology of cannabis use from cannabis use disorder is important," says Deepak Cyril D’Souza, MD, director of YC-SCAN2 . We are pleased that support from YC-SCAN2 led to this interesting paper.”
Other Yale researchers involved in the study are Qianyu Chen, Jun He, Dan Qiu, Ziang Xu, Zhongzheng Mao, Huaigui Liu, and Brenda Cabrera-Mendoza.